Two of the most-studied recovery peptides in preclinical research. Different mechanisms, different applications, often combined. Here's what the published literature says about each.
| Published studies | 100+ |
| Primary mechanisms | Musculoskeletal signaling, angiogenesis, gut epithelium |
| Origin | Gastric juice peptide fragment |
| Molecular weight | 1,419 Da (15 amino acids) |
| Stability | Highly stable in gastric acid |
| Research focus areas | Tendon/ligament, GI tract, muscle tissue, bone healing |
| SMART MD purity | 99.1% HPLC |
| Published studies | 50+ |
| Primary mechanisms | Cell migration, wound repair, anti-inflammatory |
| Origin | Synthetic fragment of Thymosin Beta 4 |
| Molecular weight | 4,963 Da (43 amino acids) |
| Stability | Requires reconstitution, temp-sensitive |
| Research focus areas | Cardiac tissue, hair follicle, systemic inflammation, wound models |
| SMART MD purity | 99%+ HPLC |
BPC-157 is a 15-amino-acid fragment derived from gastric juice, studied primarily in preclinical models of musculoskeletal tissue signaling (tendon-to-bone healing, ligament repair) and gut epithelium protection. It's notably stable in acidic environments. TB-500 is a 43-amino-acid synthetic fragment of Thymosin Beta 4, a naturally occurring peptide found in virtually all human cells. TB-500 is studied in preclinical models of cell migration, wound repair, cardiac tissue signaling, and systemic anti-inflammatory pathways. Both are research-use-only compounds verified by SMART MD with 3-lab independent COAs.
Yes — researchers frequently study BPC-157 and TB-500 in combination. The Wolverine Blend (BPC-157 5mg + TB-500 5mg in a single vial) is SMART MD's most-ordered product for this reason. Preclinical literature suggests complementary mechanisms: BPC-157's angiogenesis and localized tissue signaling combined with TB-500's systemic cell migration and anti-inflammatory pathways. Both are verified at 99%+ HPLC purity with lot-specific 3-lab COAs. View Wolverine Blend →
BPC-157 has more published preclinical studies (100+ vs 50+ for TB-500). BPC-157's research is concentrated in musculoskeletal and GI models, while TB-500's literature spans cardiac, dermal, and systemic inflammation models. Both have substantial preclinical evidence bases but neither has completed human clinical trials for therapeutic indications. All research references are for preclinical and in vitro contexts only.
Research-grade BPC-157 and TB-500 with 3-lab independent COA verification (HPLC + mass spec + LAL endotoxin) are available at SMART MD Peptides. Every batch is publicly verifiable at smartmdpeptides.com/verify. Available individually (BPC-157 5mg/10mg/20mg, TB-500 5mg/10mg) or as the combined Wolverine Blend. For research purposes only.
The Wolverine Blend combines BPC-157 (5mg) + TB-500 (5mg) in a single lyophilized vial. Our most-ordered compound — 150+ combined preclinical references. 99.2% HPLC verified. 3-lab COA.
Buy Wolverine Blend →